Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2024-11-27 00:00:00 ET · period of report 2024-11-25 · accession 0001714899-24-000235 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-27 | 2024-11-25 | DNLI | Ho Carole | Chief Medical Off | M - OptEx | $0.68 | +17.8K | 136.7K | +15% | +$12.1K |
| D | 2024-11-27 | 2024-11-25 | DNLI | Ho Carole | Chief Medical Off | M - OptEx | $0.00 | -17.8K | 107.2K | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-25 | M | A | 17,845 | $0.68 | 136,655 | D | — | — | (F1) Includes 118,810 Unvested RSUs. |
| 2 | Derivative | Stock Option (right to buy) | 2024-11-25 | M | D | 17,845 | $0.00 | 107,155 | D | $0.68 · — to 2025-08-20 | 17,845 Common Stock | (F4) The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. |